Questions? +1 (202) 540-8337 Login
Trusted News Since 1995
A service for medical industry professionals · Tuesday, August 14, 2018 · 458,725,887 Articles · 3+ Million Readers

Nicotinamide Phosphoribosyltransferase - Disease Assessment and Therapeutics Analysis Forecasts to 2024

PUNE, INDIA, April 3, 2018 /EINPresswire.com/ -- WiseGuyReports.com with their unique quality of simplifying the market research study, presents a deep diving study report “Nicotinamide Phosphoribosyltransferase - Pipeline Review, H1 2018”

Nicotinamide Phosphoribosyltransferase

Overview

Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) - Nicotinamide phosphoribosyltransferase (NAmPRTase) is an enzyme encoded by the PBEF1 gene. This protein has also been reported to be a cytokine (PBEF) that promotes B cell maturation and inhibits neutrophil apoptosis.  

NAmPRTase catalyzes the condensation of nicotinamide with 5-phosphoribosyl-1-pyrophosphate to yield nicotinamide mononucleotide, one step in the biosynthesis of nicotinamide adenine dinucleotide. The protein is an adipokine that is localized to the bloodstream and has various functions, including the promotion of vascular smooth muscle cell maturation and inhibition of neutrophil apoptosis. It also activates insulin receptor and has insulin-mimetic effects, lowering blood glucose and improving insulin sensitivity.

Click here for sample report @ https://www.wiseguyreports.com/sample-request/3079826-nicotinamide-phosphoribosyltransferase-visfatin-or-pre-b-cell-colony

 

Major Key Players:

Angelini Group

Calico LLC

Eli Lilly and Co

Genentech Inc

Karyopharm Therapeutics Inc

OncoTartis Inc

Nicotinamide Phosphoribosyltransferase Industry Major Outlook

Pharmaceutical and Healthcare latest pipeline guide Nicotinamide Phosphoribosyltransferase    - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Nicotinamide Phosphoribosyltransferase   , complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Nicotinamide Phosphoribosyltransferase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) pipeline Target constitutes close to 8 molecules. Out of which approximately 8 molecules are developed by Companies. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 3, 1, 1 and 2 respectively.

Nicotinamide Phosphoribosyltransferase pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Nicotinamide Phosphoribosyltransferase - Competitive Analysis

Key players are making innovative developments in Nicotinamide Phosphoribosyltransferase industry.  The same will help in improving the market performance. Heavy investments are made by major players in the R&D sector

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Nicotinamide Phosphoribosyltransferase.

The pipeline guide reviews pipeline therapeutics for Nicotinamide Phosphoribosyltransferase by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. 

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Nicotinamide Phosphoribosyltransferase therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Nicotinamide Phosphoribosyltransferase therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 

The pipeline guide reviews latest news related to pipeline therapeutics for Nicotinamide Phosphoribosyltransferase.

.Continued

For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/3079826-nicotinamide-phosphoribosyltransferase-visfatin-or-pre-b-cell-colony

About Us

Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.

Contact Us:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

www.wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

Norah Trent
WiseGuy Research Consultants Pvt. Ltd.
+1 646 845 9349 / +44 208 133 9349
email us here

Powered by EIN Presswire